๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Quality assurance for interventions in clinical trials: Multicenter data monitoring, data management, and analysis

โœ Scribed by Brad H. Pollock


Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
606 KB
Volume
74
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Statistical analysis of quality of life
โœ Andrea B. Troxel; Diane L. Fairclough; Desmond Curran; Elizabeth A. Hahn ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 255 KB ๐Ÿ‘ 3 views

We summarize issues that arise when considering quality of life (QOL) data in cancer clinical trials, especially those related to missing data. We describe different types of missing data mechanisms, and discuss ways of assessing and testing missing data mechanisms. A section on presentation of stud

Item response models for longitudinal qu
โœ Jeffrey A. Douglas ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 140 KB ๐Ÿ‘ 2 views

Assessment of quality of life is becoming standard in clinical trials. A popular method for measuring quality of life is with instruments which utilize multiple-item subscales, in which each item is scored on a Likert scale. Most statistical methods for the analysis of quality of life data in clinic

MULTI-LEVEL MODELS FOR REPEATED MEASUREM
โœ HEATHER J. BEACON; SIMON G. THOMPSON ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 985 KB

Quality of life data present considerable statistical challenges because of their longitudinal and multi- dimensional nature, and also because the available data are often very unbalanced through missing values. Here we exemplify the potential of multi-level models, that is, hierarchical random coe

Comparison of several model-based method
โœ Diane L. Fairclough; Harriet F. Peterson; David Cella; Phil Bonomi ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 250 KB ๐Ÿ‘ 2 views

This paper considers five methods of analysis of longitudinal assessment of health related quality of life (QOL) in two clinical trials of cancer therapy. The primary difference in the two trials is the proportion of participants who experience disease progression or death during the period of QOL a